- News / Events
- Company Information
- Financial Information
- Stock Data
- SEC Filings
- Corporate Governance
Investing in the BioPharma Market How the Numbers Support the Projections of Continued Success Into 2016
A trend has surfaced lately that indicates that the future of Endonovo Therapeutics is very, very bright. Over the past few years, accounting for all available global figures, spending on biopharmaceuticals has risen to around $160 billion. This number is projected to rise to $200 billion by the end of 2016, and the growth is not projected to stop at any point past that. As the population of the United States, and indeed, the world, grows, the demand for quality hightech healthcare can only increase.
Those investing in biotechnology industry companies like Endonovo are finding themselves sitting in the comfortable position of knowing that they have a few dollars tied into the everburgeoning pharmaceutical market. It's money that very simply can't miss the bullseye, even if financial experts and pundits alike haven't caught on yet.
People are going to continue to get sick. There are more and more of us inhabiting the world each day, and those people will require health care when illness strikes. It is unlikely that we as a society will revert to yesterday's methods of healing, so investing in the biotechnology industry, which is on the leading edge of medicine, is a solid move.
It has been calculated that the amount of revenue drawn in by pharmaceutical medicine worldwide totals around $157 billion. Fluctuations in the market may mean that you can grab a slice of the market's most likely to succeed pies before too many people hear about it.